Eight pharmaceutical stocks are moving up in their overall rating this week, according to the Portfolio Grader database. Every one of these is graded an “A” (“strong buy”) or “B” overall (“buy”).

This week, NuPathe Inc. (PATH) is showing significant improvement as the company’s rating hops from a C (“hold”) to a B (“buy”). NuPathe develops pharmaceutical products used for the treatment and management of neurological and psychiatric diseases. In Portfolio Grader’s specific subcategories of Earnings Momentum and Earnings Revisions, PATH also gets A’s. For more information, get Portfolio Grader’s complete analysis of PATH stock.

GW Pharmaceuticals PLC Sponsored ADR’s (GWPH) ratings are looking better this week, moving up to a B from last week’s C. For more information, get Portfolio Grader’s complete analysis of GWPH stock.

Watson Pharmaceuticals (WPI) is making headway this week, with the company’s rating improving to an A (“strong buy”) from a B (“buy”) last week. Watson develops, manufactures, markets, sells and distributes pharmaceutical products. For more information, get Portfolio Grader’s complete analysis of WPI stock.

Lipocine, Inc. (LPCN) boosts its rating from a B to an A this week. Lipocine is engaged in the development of pharmaceutical products in the areas of men’’s and women’’s health. For more information, get Portfolio Grader’s complete analysis of LPCN stock.

This week, Paratek Pharmaceuticals Inc (PRTK) pushes up from a B to an A rating. For more information, get Portfolio Grader’s complete analysis of PRTK stock.

This week, Pain Therapeutics, Inc.’s (PTIE) ratings are up from a B last week to an A. Pain Therapeutics develops safer or more efficacious drugs for use in pain management, particularly in the area of opioid painkillers. For more information, get Portfolio Grader’s complete analysis of PTIE stock.

The rating of Cardiome Pharma (CRME) moves up this week, rising from a C to a B. Cardiome Pharma focuses on the discovery, development, and commercialization of drugs to treat or prevent cardiovascular and other diseases. For more information, get Portfolio Grader’s complete analysis of CRME stock.

This is a strong week for AbbVie, Inc. (ABBV). The company’s rating climbs to B from the previous week’s C. AbbVie, a research-based biopharmaceutical company, engages in the discovery, development, manufacture, and sale of pharmaceutical products worldwide. For more information, get Portfolio Grader’s complete analysis of ABBV stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.